Evaluation of dyslipidaemia and the impact of hypolipidemic therapy on prognosis in high and very high risk patients through the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) Registry

[Display omitted] The use of statins in the treatment of hyperlipidaemia leads to a significant decrease in cardiovascular (CV) endpoints, and therapy effects are proportional to the reduction of cholesterol levels. In Poland, information about the effects of statin therapy is scarcely available. Th...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacological research 2018-06, Vol.132, p.204-210
Main Authors: Dyrbuś, Krzysztof, Osadnik, Tadeusz, Desperak, Piotr, Desperak, Aneta, Gąsior, Mariusz, Banach, Maciej
Format: Article
Language:English
Subjects:
Coronary artery disease
Hyperlipidaemia
Secondary prevention
Statins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] The use of statins in the treatment of hyperlipidaemia leads to a significant decrease in cardiovascular (CV) endpoints, and therapy effects are proportional to the reduction of cholesterol levels. In Poland, information about the effects of statin therapy is scarcely available. The information gathered in the Hyperlipidaemia Therapy in the tERtiary Cardiological cEnTer (TERCET) Registry on high-risk and very high-risk patients might improve our knowledge on this issue and help to introduce suitable activities. The main aim of the TERCET Registry is to achieve the target value of low density lipoprotein cholesterol (LDL-C) during a 1-year follow-up: LDL-C
ISSN:1043-6618
1096-1186
DOI:10.1016/j.phrs.2017.12.015